Tokuyama Valuation Multiples
Tokuyama is valued at $1.6B as of November 2026, a 1.1x revenue multiple. In the last 12 months, Tokuyama revenue was $2.3B and Tokuyama EBITDA was $378M.
Tokuyama Overview
About Tokuyama
Tokuyama Corp mainly manufactures and sells chemicals, specialty products, cement and functional materials. The company operates in Chemicals segment offers soda ash, caustic soda, calcium chloride, silicate soda, propylene oxide and methylene chloride; Advanced Electronic Materials Segment manufactures and sells high-purity isopropyl alcohol, photoresist developers, industrial isopropyl alcohol; Cement segment offers portland cement, ready-mixed concrete and cementitious solidified materials and the Life Sceince segment offers polypropylene film, resin sashes and others; Environmental Business Segment manufactures and sells ion exchange membranes and other related products and recycle waste gypsum boards; and others segment focuses on transportation services, and real estate management.
Founded
1918
HQ
Employees
6.9K
Website
Financials (LTM)
EV
$2.5B
Valuation Multiples
Start free trial
Tokuyama Financials
Tokuyama reported last 12-month revenue of $2.3B and EBITDA of $378M.
In the same LTM period, Tokuyama generated $795M in gross profit, $378M in EBITDA, and $224M in net income.
Revenue (LTM)
Tokuyama P&L
In the most recent fiscal year, Tokuyama reported revenue of $2.2B and EBITDA of $379M.
Tokuyama is profitable as of last fiscal year, with gross margin of 36%, EBITDA margin of 17%, and net margin of 6%.
Financial data powered by Morningstar, Inc.
Tokuyama Stock Performance
Tokuyama has current market cap of $1.6B, and enterprise value of $2.5B.
Market Cap Evolution
Tokuyama's stock price is $22.54.
Tokuyama share price decreased by 9.6% in the last 30 days.
Tokuyama has an EPS (earnings per share) of $1.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $1.6B | 0.0% | -9.6% | - | - | $1.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTokuyama Valuation Multiples
Tokuyama trades at 1.1x EV/Revenue multiple, and 6.6x EV/EBITDA.
EV / Revenue (LTM)
Tokuyama Financial Valuation Multiples
As of November 8, 2026, Tokuyama has market cap of $1.6B and EV of $2.5B.
Tokuyama has a P/E ratio of 7.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tokuyama Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tokuyama Margins & Growth Rates
Tokuyama grew revenue by 11% but EBITDA decreased by 0% in the last fiscal year.
In the most recent fiscal year, Tokuyama reported gross margin of 36%, EBITDA margin of 17%, and net margin of 6%.
Tokuyama Margins
Tokuyama Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Tokuyama Operational KPIs
Tokuyama's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Tokuyama Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Tokuyama competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Tokuyama
Tokuyama has acquired 1 company to date.
Last acquisition by Tokuyama was on April 22nd 2025. Tokuyama acquired JSR (in vitro diagnostics business unit) for $574M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Tokuyama
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} JSR (in vitro diagnostics business unit) | |
| Description | JSR (in vitro diagnostics business unit) was the diagnostics reagents and diagnostics materials business of the Japanese materials group JSR. It combined the Japanese diagnostics company Medical & Biological Laboratories with JSR Life Sciences' diagnostic materials operations. The business developed and sold clinical diagnostic reagents, pathology and cytology testing products and diagnostic raw materials such as magnetic particles to clinical laboratories, diagnostic manufacturers and research institutions. Revenue came from product sales of reagents, kits and materials in Japan and overseas. In 2025 it was separated into a newly established company for transfer to Tokuyama. Its customers included clinical laboratories, hospitals, diagnostic equipment makers and academic researchers. The business combined products developed in Japan with materials supplied to manufacturers of immunoassay systems worldwide, and it formed one of the main pillars of JSR's life sciences segment. |
| HQ Country | |
| HQ City | Tokyo |
| Deal Date | 22 Apr 2025 |
| Valuation | $574M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Tokuyama acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Tokuyama
Tokuyama has invested in 1 company to date.
Latest investment by Tokuyama was on December 17th 2019. Tokuyama invested in 1366 Technologies in their $18M Series E round (EV/Revenue multiple available to Pro users).
Latest Investments by Tokuyama
| Description | 1366 Technologies is a Bedford-headquartered manufacturer of low-cost silicon wafers for photovoltaic solar cells. The company's Direct Wafer process reduces production costs by 50 percent, compatible with existing module lines. Founded in 2008, 1366 Tech shipped over 100 megawatts of wafers before its 2020 acquisition by a strategic buyer, advancing U.S. solar manufacturing. | 1366 Technologies is a Bedford-headquartered manufacturer of low-cost silicon wafers for photovoltaic solar cells. The company's Direct Wafer process reduces production costs by 50 percent, compatible with existing module lines. Founded in 2008, 1366 Tech shipped over 100 megawatts of wafers before its 2020 acquisition by a strategic buyer, advancing U.S. solar manufacturing. |
| HQ Country |  | |
| HQ City | - | - |
| Deal Date | 17 Dec 2019 | 15 Oct 2013 |
| Round | Series E | Series C |
| Raised | $18M | $15M |
| Investors | Energy Technology Ventures; Hanwha Chemical Corporation; Breakthrough Energy Ventures; Polaris Partners; Haiyin Capital; VantagePoint Capital Partners; VM Capital; Tokuyama; North Bridge Venture Partners & Growth Equity | Energy Technology Ventures; Polaris Partners; VantagePoint Capital Partners; Tokuyama; North Bridge Venture Partners & Growth Equity |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Tokuyama investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tokuyama
| When was Tokuyama founded? | Tokuyama was founded in 1918. |
| Where is Tokuyama headquartered? | Tokuyama is headquartered in Japan. |
| How many employees does Tokuyama have? | As of today, Tokuyama has over 6K employees. |
| Is Tokuyama publicly listed? | Yes, Tokuyama is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Tokuyama? | Tokuyama trades under 4043 ticker. |
| When did Tokuyama go public? | Tokuyama went public in 1949. |
| Who are competitors of Tokuyama? | Tokuyama main competitors include |
| What is the current market cap of Tokuyama? | Tokuyama's current market cap is $1.6B. |
| What is the current revenue of Tokuyama? | Tokuyama's last 12 months revenue is $2.3B. |
| What is the current revenue growth of Tokuyama? | Tokuyama revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Tokuyama? | Current revenue multiple of Tokuyama is 1.1x. |
| What is the current EBITDA of Tokuyama? | Tokuyama's last 12 months EBITDA is $378M. |
| What is Tokuyama's EBITDA margin? | Tokuyama's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Tokuyama? | Current EBITDA multiple of Tokuyama is 6.6x. |
| What is the current FCF of Tokuyama? | Tokuyama's last 12 months FCF is ($147M). |
| What is Tokuyama's FCF margin? | Tokuyama's last 12 months FCF margin is (6%). |
| What is the current EV/FCF multiple of Tokuyama? | Current FCF multiple of Tokuyama is (16.9x). |
| How many companies Tokuyama has acquired to date? | As of November 2026, Tokuyama has acquired 1 company. |
| What was the largest acquisition by Tokuyama? | $574M acquisition of JSR (in vitro diagnostics business unit) on 22nd April 2025 was the largest M&A Tokuyama has done to date. |
| What companies Tokuyama acquired? | Tokuyama acquired JSR (in vitro diagnostics business unit). |
| In how many companies Tokuyama has invested to date? | As of November 2026, Tokuyama has invested in 1 company. |
| What was the last Tokuyama investment? | On 17th December 2019 Tokuyama invested in 1366 Technologies, participating in a $18M Series E round, alongside Energy Technology Ventures, Hanwha Chemical Corporation, Breakthrough Energy Ventures, Polaris Partners, Haiyin Capital, VantagePoint Capital Partners, VM Capital, and North Bridge Venture Partners & Growth Equity. |
| In what companies Tokuyama invested in? | Tokuyama invested in 1366 Technologies. |
Lists including Tokuyama
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.